Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


FluoroPharma Medical, Inc. Announces $1.5M Equity Financing

MONTCLAIR, NJ -- (Marketwire) -- 11/20/12 -- FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that it completed a private placement on November 19, 2012 of its shares of common stock and warrants in the aggregate amount of $1,546,250. The private placement consisted of the issuance of 1,819,118 shares of the company's common stock and 1,819,118 common stock purchase warrants with an exercise price of $0.90 per share and a term of one year. The company plans to use the net proceeds from the private placement for working capital.

"We are pleased that the additional funding will enable us to further advance our most promising portfolio of diagnostic imaging products, providing healthcare professionals with new products that will expand and improve their diagnostic capabilities and contribute to earlier, more accurate diagnosis of disease," said Thijs Spoor, Chairman, CEO and President of FluoroPharma Medical. "FluoroPharma's goal is to enable personalized medicine by enabling the physician to prescribe the right medicine, for the right person, at the right time, for the right outcome. This is only possible with the right diagnostics."

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities referenced herein in any jurisdiction to any person.

The shares of common stock issued in connection with the transactions have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements. The company has agreed to file a registration statement providing for the resale of the shares of common stock and the shares underlying the warrants issued in the private placement following the closing. The company will file a Form 8-K with the Securities and Exchange Commission describing in more detail the terms of the private placement.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston.

The company's goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

The company's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease and agents that could potentially be used for imaging specific cancers.

For more information on the company, please visit: www.fluoropharma.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to clinical trials, financing and strategic agreements and relationships, our need for substantial additional funds, government regulation, patent and intellectual property matters; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Email: Email Contact
Phone: 212-554-5466

Media:
Carol J. Perlman
FluoroPharma Medical, Inc.
Email: Email Contact
Phone: 917-592-9260

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Ukraine sits on the precipice of civil war. Beneath the ostensible storyline of protests against the government of Viktor Yanukovych and recent laws it's enacted lies what is likely an insuperable rift between the eastern and western regions of the country. The east, archetyped by ...
A web of large-scale business and trade connections is making it difficult to imagine a successful strategy and tactics to counter Vladimir Putin's Crimean land grab. Putin himself seems to be unconcerned with nuance and complication, as he bulldozes onward. Russia's abrupt takeove...
I had a fun conversation with Mark Van Rijmenam (@VanRijmenam) a couple of weeks ago about cloud computing, Big Data, and the IoT. Mark runs BigData-Startups.com in Den Haag, Netherlands. We were mutually amused that he had chosen the name Think Bigger for his new book just as I had ch...
“Vote early and vote often.” Back in the 1920s and ’30s, when neither election technology nor oversight were as effective as they are today, and the likes of Al Capone were at work gaming the system, this phrase wasn’t a joke. It was a best practice. If you want guaranteed results, wh...
If you listen to the persistent murmur in the market surrounding the Internet of Things right now, you'd believe that it's all about sensors. Sensors and big data. Sensors that monitor everything from entertainment habits to health status to more mundane environmental data about your h...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE